Background: The association of treatment resistance with physical and psychiatric comorbidities remains unclear in elderly patients with late-onset major depressive disorder (MDD).
Methods: Participants were selected from the Taiwan National Health Insurance Research Database. We included patients aged ≥ 65 years with first-episode MDD (ICD-9-CM codes: 296.2X and 296.3X) between January 1, 2001, and December 31, 2010. All participants were followed for 1 year to investigate the incidence of treatment resistance. Treatment-resistant depression (TRD) was defined as unresponsiveness to at least 2 antidepressants, and treatment-resistant tendency (TRT) was defined as unresponsiveness to the first antidepressant. Physical comorbidities were assessed with the Charlson Comorbidity Index (CCI).
Results: 27,189 patients with late-onset MDD were included, among whom 16.6% had the diagnosis of anxiety disorders, 1.5% had alcohol use disorders, and 1.6% had substance use disorder. For physical comorbidities, only 16.6% of patients had a CCI score of 0. During the first year of treatment, 22.1% of patients met TRT criteria, and 1.6% developed TRD. Anxiety disorders (odds ratio: 2.06; 95% confidence interval [CI], 1.67–2.53), substance use disorders (2.11; 95% CI, 1.26–3.53), and higher CCI scores (1.06; 95% CI, 1.01–1.10) were significantly associated with TRD, while anxiety disorders (1.44; 95% CI, 1.34–1.55) and higher CCI scores (1.06; 95% CI, 1.05–1.08) were significantly associated with TRT.
Conclusions: Approximately one-fourth of elderly patients responded poorly to the first antidepressant treatment during the first year of late-onset MDD. Psychiatric comorbidities were more associated with the risk of early TRT than were physical comorbidities.
Continue Reading...
Members enjoy unlimited free PDF downloads as part of their subscription! Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
Depression and Other Common Mental Disorders. Global Health Estimates. World Health Organization; 2017:1–24.
Mojtabai R, Olfson M. Major depression in community-dwelling middle-aged and older adults: prevalence and 2- and 4-year follow-up symptoms. Psychol Med. 2004;34(4):623–634. PubMedCrossRef
Byers AL, Yaffe K, Covinsky KE, et al. High occurrence of mood and anxiety disorders among older adults: The National Comorbidity Survey Replication. Arch Gen Psychiatry. 2010;67(5):489–496. PubMedCrossRef
Lyness JM, Caine ED, King DA, et al. Psychiatric disorders in older primary care patients. J Gen Intern Med. 1999;14(4):249–254. PubMedCrossRef
Hoover DR, Siegel M, Lucas J, et al. Depression in the first year of stay for elderly long-term nursing home residents in the USA. Int Psychogeriatr. 2010;22(7):1161–1171. PubMedCrossRef
Brodaty H, Luscombe G, Parker G, et al. Early and late onset depression in old age: different aetiologies, same phenomenology. J Affect Disord. 2001;66(2-3):225–236. PubMedCrossRef
Bruce MLMG, McAvay GJ, Raue PJ, et al. Major depression in elderly home health care patients. Am J Psychiatry. 2002;159(8):1367–1374. PubMedCrossRef
Thomas L, Mulsant BH, Solano FX, et al. Response speed and rate of remission in primary and specialty care of elderly patients with depression. Am J Geriatr Psychiatry. 2002;10(5):583–591. PubMedCrossRef
Whyte EM, Basinski J, Farhi P, et al. Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65(12):1634–1641. PubMedCrossRef
Alexopoulos GS, Canuso CM, Gharabawi GM, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry. 2008;16(1):21–30. PubMedCrossRef
Lenze EJ, Schulz R, Martire LM, et al. The course of functional decline in older people with persistently elevated depressive symptoms: longitudinal findings from the Cardiovascular Health Study. J Am Geriatr Soc. 2005;53(4):569–575. PubMedCrossRef
Lenze EJ. Comorbidity of depression and anxiety in the elderly. Curr Psychiatry Rep. 2003;5(1):62–67. PubMedCrossRef
Liang CS, Chung CH, Ho PS, et al. Superior anti-suicidal effects of electroconvulsive therapy in unipolar disorder and bipolar depression. Bipolar Disord. 2018;20(6):539–546. PubMedCrossRef
Liang CS, Bai YM, Hsu JW, et al. The risk of sexually transmitted infections following first-episode schizophrenia among adolescents and young adults: a cohort study of 220–545 subjects. Schizophr Bull. 2020;46(4):795–803. PubMedCrossRef
Huang JS, Yang FC, Chien WC, et al. Risk of substance use disorder and its associations with comorbidities and psychotropic agents in patients with autism. JAMA Pediatr. 2021;175(2):e205371. PubMedCrossRef
Chen MH, Lan WH, Hsu JW, et al. Risk of developing type 2 diabetes in adolescents and young adults with autism spectrum disorder: a nationwide longitudinal study. Diabetes Care. 2016;39(5):788–793. PubMedCrossRef
Chen MH, Pan TL, Li CT, et al. Risk of stroke among patients with post-traumatic stress disorder: nationwide longitudinal study. Br J Psychiatry. 2015;206(4):302–307. PubMedCrossRef
Chen MH, Su TP, Chen YS, et al. Attention deficit hyperactivity disorder, tic disorder, and allergy: is there a link? a nationwide population-based study. J Child Psychol Psychiatry. 2013;54(5):545–551. PubMedCrossRef
Cheng CM, Chang WH, Chen MH, et al. Co-aggregation of major psychiatric disorders in individuals with first-degree relatives with schizophrenia: a nationwide population-based study. Mol Psychiatry. 2018;23(8):1756–1763.PubMed
Li CT, Bai YM, Huang YL, et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry. 2012;200(1):45–51. PubMedCrossRef
Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649–659. PubMedCrossRef
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. PubMedCrossRef
Kautzky A, Dold M, Bartova L, et al. Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. Acta Psychiatr Scand. 2019;139(1):78–88. PubMedCrossRef
Beekman AT, de Beurs E, van Balkom AJ, et al. Anxiety and depression in later life: co-occurrence and communality of risk factors. Am J Psychiatry. 2000;157(1):89–95. PubMedCrossRef
Jeste ND, Hays JC, Steffens DC. Clinical correlates of anxious depression among elderly patients with depression. J Affect Disord. 2006;90(1):37–41. PubMedCrossRef
Schoevers RA, Beekman AT, Deeg DJ, et al. Comorbidity and risk-patterns of depression, generalised anxiety disorder and mixed anxiety-depression in later life: results from the AMSTEL study. Int J Geriatr Psychiatry. 2003;18(11):994–1001. PubMedCrossRef
DeLuca AK, Lenze EJ, Mulsant BH, et al. Comorbid anxiety disorder in late life depression: association with memory decline over four years. Int J Geriatr Psychiatry. 2005;20(9):848–854. PubMedCrossRef
Morimoto SS, Kanellopoulos D, Manning KJ, et al. Diagnosis and treatment of depression and cognitive impairment in late life. Ann N Y Acad Sci. 2015;1345(1):36–46. PubMedCrossRef
Brenner P, Brandt L, Li G, et al. Substance use disorders and risk for treatment resistant depression: a population-based, nested case-control study. Addiction. 2020;115(4):768–777. PubMedCrossRef
Brenner P, Brandt L, Li G, et al. Treatment-resistant depression as risk factor for substance use disorders-a nation-wide register-based cohort study. Addiction. 2019;114(7):1274–1282. PubMedCrossRef
Wu LT, Blazer DG. Substance use disorders and psychiatric comorbidity in mid and later life: a review. Int J Epidemiol. 2014;43(2):304–317. PubMedCrossRef
Kuerbis A, Sacco P, Blazer DG, et al. Substance abuse among older adults. Clin Geriatr Med. 2014;30(3):629–654. PubMedCrossRef
Wells KB, Golding JM, Burnam MA. Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry. 1988;145(8):976–981. PubMedCrossRef
Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24(6):1069–1078. PubMedCrossRef
Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15(9):505–522. PubMedCrossRef
Fiske A, Wetherell JL, Gatz M. Depression in older adults. Annu Rev Clin Psychol. 2009;5(1):363–389. PubMedCrossRef
Chen MH, Pan TL, Hsu JW, et al. Attention-deficit hyperactivity disorder comorbidity and antidepressant resistance among patients with major depression: a nationwide longitudinal study. Eur Neuropsychopharmacol. 2016;26(11):1760–1767. PubMedCrossRef
Chan YE, Chen MH, Tsai SJ, et al. Treatment-resistant depression enhances risks of dementia and Alzheimer’s disease: a nationwide longitudinal study. J Affect Disord. 2020;274:806–812. PubMedCrossRef